Abstracts Archive - Page 569 of 1683 - ATC Abstracts

2019 American Transplant Congress
Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient
S. C. Jordan¹, R. Vescio², M. Toyoda³, N. Ammerman¹, E. Huang¹, A. Peng¹, S. Sethi¹, R. Najjar¹, K. Lim¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR) is a severe form of rejection mediated by B-cells, plasma cells and antibodies. The consequences to the patients with ABMR are…
2019 American Transplant Congress
Cluster Analysis of Microvascular Inflammation in Indication Biopsies Unveils Distinct Pathological and Immunological Phenotypes with Prognostic Implications
J. Malheiro¹, A. Silva¹, S. Santos¹, S. Tafulo², L. Martins¹, L. Dias¹, A. Castro-Henriques¹
¹Centro Hospitalar do Porto, Porto, Portugal, ²IPST_Porto, Porto, Portugal
*Purpose: We aimed to define distinct pathological and immunological clusters of 80 cases of MVI diagnosed in indication biopsies and evaluate their prognostic implications.*Methods: The…
2019 American Transplant Congress
Effect of Race and Antibody-Mediated Injury on Outcomes after Early Subclinical Inflammation
E. P. Kasik, M. E. Seifert, M. Bernard, G. Agarwal, H. Fatima, R. Gaston, B. Julian, C. Kew, V. Kumar, S. Mehta, S. Ong, F. Rosenblum, G. Towns, R. B. Mannon
University of Alabama, Birmingham, AL
*Purpose: The impact of subclinical inflammation (SCI) on transplant outcomes has been variable, based on previous studies in homogeneous cohorts with relatively low immunologic risk.…
2019 American Transplant Congress
Association between CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients
K. Nanmoku, T. Shinzato, T. Kubo, T. Shimizu, T. Yagisawa
Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan
*Purpose: Rituximab, which suppresses antibody production, is widely used for desensitization in ABO-incompatible and donor-specific antibody-positive kidney transplantation. However, data regarding the effects of individual…
2019 American Transplant Congress
Pre-emptive Ivig For Dsa Positive Living Donor Kidney Transplant Recipients
B. Abdalla¹, D. Kellner², A. Diaz², Y. Zheng³, E. Reed⁴, Q. J. Zhang⁴
¹Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³UCLA Immunogenetics Center, Los Angeles, CA, ⁴Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Intravenous immunoglobulin (IVIG) is used in desensitization regimens to modulate anti-human leukocyte antigen (HLA) donor-specific antibody (DSA) to facilitate transplantation of sensitized patients, however,…
2019 American Transplant Congress
Incidence of De Novo Donor Specific Antibodies and Treatment Response for AMR in Pediatric Kidney Transplant Recipients
S. Gattis¹, R. Liverman¹, A. Serluco¹, J. Yin¹, H. C. Sullivan², R. A. Bray³, H. M. Gebel³, S. Jernigan⁴, R. George⁴, P. D. Winterberg⁴, R. Garro⁴
¹Children's Healthcare of Atlanta, Atlanta, GA, ²Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, ³Emory University Hospital, Atlanta, GA, ⁴Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
*Purpose: Antibody-mediated rejection (AMR) is a significant complication in renal transplant patients. The aim of this study was to evaluate the incidence of de novo…
2019 American Transplant Congress
Evaluation Of Complement-related Factors In Tma Post-kidney Transplantation: A Retrospective Multicenter Study
N. Fujiyama¹, M. Tasaki², H. Harada³, K. Tsutahara⁴, A. Matsumoto⁵, Y. Hara⁶, M. Okumi⁷, K. Saito², Y. Watarai⁸, N. Inoue⁹, N. Wakamiya⁹, S. Satoh¹
¹Center for Kidney Disease and Transplantaion, Akita University Hospital, Akita, Japan, ²Department of Urology, Niigata University, Niigata, Japan, ³Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan, ⁴Department of Urology, Osaka General Medical Center, Osaka, Japan, ⁵Department of Urology, The University of Tokyo, Tokyo, Japan, ⁶Department of Nephrolog, Shinsyu University Hospital, Shinsyu, Japan, ⁷Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan, ⁸Department of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan, ⁹The Japanese Association for Complement Research, Osaka, Japan
*Purpose: Post-kidney transplant thrombotic microangiopathy (KT-TMA) is a poor prognostic complication that causes a high rate of graft loss. In this study, we investigated KT-TMA-associated…
2019 American Transplant Congress
Infectious Complications after Treatment of Antibody-Mediated Kidney Allograft Rejection: A National Cohort Study
N. Perrottet¹, D. Golshayan², O. Manuel², V. Aubert², M. Koller³, K. Hadaya⁴, L. Bühler⁴, T. Mueller⁵, U. Huynh-Do⁶, S. Dahdal⁶, I. Binet⁷, M. Dickenmann³, S. Schaub³, J. Steiger³, M. Pascual², M. Fernández-Ruiz²
¹Pharmacy, CHUV, Lausanne, Switzerland, ²CHUV, Lausanne, Switzerland, ³USB, Basel, Switzerland, ⁴HUG, Geneva, Switzerland, ⁵USZ, Zurich, Switzerland, ⁶Inselspital, Bern, Switzerland, ⁷KSSG, St. Gallen, Switzerland
*Purpose: Multimodal therapeutic strategies used to treat acute antibody-mediated rejection (AMR) could enhance the risk of infection. However, data in this context are scarce.*Methods: We…
2019 American Transplant Congress
Outcomes Of Treatment Of Late Vs Early Acute Antibody-mediated Rejection In Renal Transplant Recipients – A Single Center Experience
R. Prashar, N. Sulejmani, A. Patel
Henry Ford Transplant Institute, Detroit, MI
*Purpose: The diagnostic accuracy and treatment options for acute antibody-mediated rejection (aABMR) in RTRs has improved over the last several years. However,response to treatment in…
2019 American Transplant Congress
Immediate Post Reperfusion In Vivo Transcriptional Responses of Individual Human Renal Allograft Cell Populations to Circulating Anti-Angiotensin II Type I Receptor Antibody
C. M. Castro -Rojas¹, N. Salomonis², K. Chetal², R. R. Alloway³, E. Woodle³, D. A. Hildeman¹
¹Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, ²Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH, ³Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH
*Purpose: Pre-existing anti-angiotensin II type I receptor (AT1R) antibodies can be a significant driver of allograft rejection. Indeed, prior work has shown that AT1R antibodies…